Current and investigational antiobesity agents and obesity therapeutic treatment targets

Obesity Research

Volumn 12, Issue 8, 2004, Pages 1197-1211

  Bays, Harold E ^a  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

Adiposopathy; Insulin; Leptin; Treatment target

Indexed keywords

AGOUTI;

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIOBESITY AGENT; INSULIN; ION CHANNEL; LEPTIN; NEW DRUG;

BASAL METABOLIC RATE; BRAIN; DIGESTIVE SYSTEM; DRUG EFFECT; HUMAN; OBESITY; PHYSIOLOGY; REVIEW;

ANTI-OBESITY AGENTS; BASAL METABOLISM; BRAIN; DIGESTIVE SYSTEM; DRUGS, INVESTIGATIONAL; HUMANS; INSULIN; ION CHANNELS; LEPTIN; NEUROTRANSMITTER AGENTS; OBESITY;

EID: 6344248911     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2004.151     Document Type: Review

References (125)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-7.
2. World Health Organization. Obesity and overweight facts. http://www.who.int/hpr/NPH/docs/gs_obesity.pdf (accessed July 2004).
3. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847-50.
4. Kushner R, Roth J. Assessment of the obese patient. Endocrinol Metab Clin North Am. 2003;32:915-33.
5. International Obesity Taskforce. http://www.iotf.org (accessed July 2004).
6. World Health Organization. Controlling the global obesity epidemic: nutrition. http://www.who.int/nut/obs.htm (accessed July 2004).
7. Bays HE, Dujovne CA. Anti-obesity drug development. Expert opinion. Invest Drugs. 2002;11:1189-204.
8. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2001;346:591-602.
9. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol. 1999;126:1487-95.
10. Wirth A, Krause J. Long-term weight loss with sibutramine. JAMA. 2001;286:1331-9.
11. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119-25.
12. Dujovne CA, Zavoral JH, Rowe E, Memdel CM. Effects of sibutramine on body weight and serum lipids. Am Heart J. 2001;142:489-97.
13. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabet Obes Metab. 2000;2:175-87.
14. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomized, double-blind, placebo controlled study. Diabet Obes Metab. 2000;2:105-12.
15. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res. 2003;11:1116-23.
16. Davidson M, Hauptman J, Digiroloamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA. 1999;281:235-42.
17. Sjöström L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167-72.
18. Mittendorfer B, Ostlund R, Patterson BW, et al. Orlistat inhibits daily cholesterol absorption. Obes Res. 2000;8(Suppl 1):43S.
19. Hejmsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321-6.
20. Kelley DE. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2002;25:1033-41.
21. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med. 2000;248:245-54.
22. Rossner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8:49-61.
23. Stone NJ, Kushner R. Effects of dietary modification and treatment of obesity. Med Clin North Am. 2000;84:95-122.
24. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am. 2000;84:441-61.
25. Consensus Statement. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes. Res. 2004;12:362-8.
26. Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. Letter to the editor: risperidone in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatr. 2000;39:545-6.
27. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:1272.
28. Bloch Y, Vardi O, Mendlovic S, Levkovitz Y, Gothelf D, Ratzoni G. Hyperglycemia from olanzapine treatment in adolescents. J Child Adolesc Psychopharmacol. 2003;13:97-102.
29. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049-56.
30. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10:633-41.
31. The Kretzman Obesity Newsletter, January 2002, Volume 9, Number 0. What's going on in obesity research. Available at: http://home.net/~brentzman/ articles/kretzman.obesity.newsletter/2002/newsletter.25.00.html (accessed July 2004).
32. GlaxoSmithKline. GlaxoSmithKline annual report 2001 - operational activities, research and development. http://www.gsk.com/financial/reports/ ar2001/annual-report-01/gskrep9.html (accessed July 2004).
33. Centers for Disease Control and Prevention. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services Interim Public Health Recommendations. MMWR. 1997;46:45.
34. Bengel D, Isaacs KR, Heils A, Lesch KP, Murphy DL. The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells. Neuroreport. 1998;9:2989-93.
35. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:255-61.
36. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2000;8:656-63.
37. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11:722-33.
38. Van Der Merwe T, Vercruysse F, Perry B, Fitchet M. A randomized, placebo-controlled study of the long-term effect of topiramate on body composition. Posters and Abstracts of the 18th International Diabetes Federation Congress, Paris, France, August 24-29, 2003.
39. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishman KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820-5.
40. Baker D, Pryce G, Giovannoni G, Thompson A J. The therapeutic potential of cannabis. Lancet Neurol. 2003;2:291-8.
41. Sapa AP. Pot teaches a munchies lesson. http://www.planetsave.com/ ViewStory.asp?ID=2909 (accessed July 2004).
42. SPG Media Limited. Rimonabant selective CB1 endocanna binoid receptor antagonist for the treatment of obesity. http://www.drugdevelopment-technology. com/projects/rimonabant/ (accessed July 2004).
43. Anthenelli RM, Despres JP. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit) and the RIO-LIPIDS Trial (Weight Reducing and Metabolic Effects in Overweight/Obese Patients with Dyslipidemia). Session Late Breaking Clinical Trials II Annual Scientific Session, New Orleans, LA, March 9, 2004.
44. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531-43.
45. Woods SC, Seeley RJ, Porte D, Schwartz MW. Signals that regulate food intake and energy homeostasis. Science. 1998;280:1378-83.
46. Heymsfield SB, Greenberg AS, Fujioka D, et al. Recombinant leptin for weight loss in obese and lean adults. JAMA. 1999;282:1568-75.
47. Mantzoros CS, Flier JS. Editorial: leptin as a therapeutic agent - trials and tribulations. J Clin Ednocrinol Metab. 2000;85:4033-9.
48. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA. Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab. 2000;85:4003-9.
49. Ettinger MP, Littlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults. JAMA. 2003;289:1826-32.
50. Regeneron Pharmaceuticals. Axokine. Press release. Regeneron announces results of phase III obesity study (3/31/2003) and Regeneron moving forward with AXOKINE phase III program for treatment of obesity (9/9/2003). http://www.regeneron.com/company/press_detail.asp?v_c_id=182 (accessed July 2004).
51. Glicklich A, Bays H, Russell T, Weinstein S, Hollander P. AXOKINE promotes weight loss in overweight and obese patients with type 2 diabetes mellitus. Poster Abstract 471-P. NAASO's 2003 Annual Meeting. Ft. Lauderdale, FL, October 11-15, 2003.
52. Balasubramaniam A. Clinical potentials of neuropeptide Y family of hormones. Am J Surg. 2002;4:430-4.
53. Wieland HA, Hamilton BS, Drist B, Doods HN. The role of NPY in metabolic homeostasis: implications for obesity therapy. Invest Drugs. 2000;9:1327-46.
54. Woolley GH, Hunt KJ. Incorporating pharmacotherapy into obesity management. Therapeutics Report Newsletter. 1999;6. Available at: http://www.brucewoolley.com/TherapeuticsReport/1999/Apr99.html (accessed July 2004).
55. Proietto J, Fam BC, Ainslie DA, Thornburn AW. Novel anti-obesity drugs. Invest Drugs. 2000;9:1317-26.
56. Damcott C, Sack P, Shuldiner AR. The genetics of obesity. Endocrine Metab Clin. 2003;32:761-86.
57. Wardlaw SL. Obesity as a neuroendocrine disease: lessons to be learned from proopiomelanocortin and melanocortin receptor mutations in mice and men. J Clin Endocrinol Metab. 2001;86:1442-6.
58. Porte D, Baskin DG, Schwartz MW. Leptin and insulin action in the central nervous system. Nutr Rev. 2002;60:S20-9.
59. Banks WA. The source of cerebral insulin. Eur J Pharmacol. 2004;19:5-12.
60. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vanderkerckhove J, Tavernier J. The ins and outs of leptin receptor activiation. FEBS Lett. 2003;546:45-50.
61. Meister B. Control of food intake via leptin receptors in the hypothalamus. Vitamin Horm. 2000;59:265-304.
62. Ono K. The P38 signal transduction pathway: activation and function. Cell Signal. 2000;12:1-13.
63. Stambe C, Atkins RC, Tesch GH, et al. Blockade of p38 alpha MAPK ameliorates acute inflammatory renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol. 2003;14:338-51.
64. Chang H, Shyu KG, Lin S, et al. The plaminogen activator inhibitor-1 gene is induced by cell adhesion through the MEK/ERK pathway. J Biomed Sci. 2003;10:738-45.
65. Reusch JEB. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol. 2001;90:19G-26G.
66. Gerozissis K. Brain insulin and feeding: a bi-directional communication. Eur J Pharmacol. 2004;490:59-70.
67. Fischer S. Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab. 2003;5:38-44.
68. Hauner H. Effect of acarbose on weight maintenance after dietary weight loss in obese subjects. Diabetes Obes Metab. 2001;3:423-7.
69. Schultes B, Oltmanns KM, Kern W, Horst LF, Born J, Peters A. Modulations of hunger by plasma glucose and metformin. Endocr Soc. 2003;88:1133-41.
70. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin. 2001;30:935-82.
71. Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin. 2003;32:855-67
72. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte FFA, and ectopic fat in pathogenesis of type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:463-78.
73. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2002;2:497-503.
74. Goldstein BJ. Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity, and related states of insulin resistance. Curr Drug Targets Immune Endocr Metabol Disord. 2001;3:265-75.
75. Bays HE, Stein EA. Pharmacotherapy for dyslipidemia - current therapies and future agents. Pharmacotherapy. 2003;4:1901-38.
76. Bodkin NL, Pill J, Meyer K, Hansen BC. The effects of K-111, a new insulin-sensitizer on metabolic syndrome in obese prediabetic rhesus monkeys. Horm Metab Res. 2003;35:617-24.
77. Kadowaki T. PPAR gamma agonists, antagonists. Nippon Yakurigaku Zasshi. 2001;118:321-6.
78. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667-70.
79. Boehm BO. The therapeutic potential of somatostatin receptor ligands in the treatment of obesity and diabetes. Invest Drugs. 2003;12:1501-9.
80. Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88:2586-92.
81. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53:143-51.
82. Szewczyk JR, Laudeman C. CCK1R agonists: a promising target for the pharmacological treatment of obesity. Curr Top Med Chem. 2003;3:837-54.
83. Albu J, Raja-Khan N. The management of the obese diabetic patient. Clin Office Pract. 2003;30:465-91.
84. th Scientific Sessions of the American Diabetes Association; June 4-8, 2004; Orlando, FL. Late breaking abstract 6.
85. Sturis J, Gotfredsen CF, Romer J, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol. 2003;140:123-32.
86. Ahren B, Simonsson E, Larsson H, et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care. 2002;25:869-75.
87. Chakrabarti R, Rajagopalan R. Diabetes and insulin resistance associated disorders: disease and therapy. Curr Sci. 2002;83:1533-8.
88. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY 3-36 physiologically inhibits food intake. Nature. 2002;418:650-3.
89. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623-30.
90. Stoeckli R, Chanda Robin, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res. 2004;12:346-50.
91. Young AA. Amylin as a neuroendocrine hormone. Scientific World J. 2001;18:24.
92. Maggs D, Shen L, Brown D, Kolterman O, Weyer C. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism. 2003;12:1638-42.
93. Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003;5:408-14.
94. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12:661-8.
95. Hu B, Jennings LL. Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type 2 diabetes mellitus. Prog Med Chem. 2003;41:167-94.
96. Hesselink MKC, Mensink M, Schrauwen P. Human uncoupling protein-3 and obesity: an update. Obes Res. 2003;11:1429-43.
97. Grover GJ, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a stategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U.S.A. 2003;100:1006-72.
98. Wolf G. Adiponectin: a regulator of energy homeostasis. Nutr Rev. 2003;61:290-2.
99. Collins CA, Kym PR. Prospects for obesity treatment: MCH receptor antagonists. Curr Opin Invest Drugs. 2003;4:386-94.
100. Lukic T, Pritchard H, Wasan KM. Disodium ascorbyl phytostanyl phosphates, FM-VP4, decreases blood lipids and body weight without observed toxicity. International Symposium on Triglycerides, Metabolic Disorders, and Cardiovascular Disease, New York, NY, July 11, 2003.
101. St-Onge MP, Lamarche B, Mauger JF, Jones PJ. Consumption of functional oil rich in phytosterols and medium chain triglyceride oil improves plasma lipid profiles. J Nutr. 2003;133:1815-20.
102. Bourque C, St-Onge MP, Papamandjaris AA, et al. Consumption of an oil composed of medium chain triacyglycerols, phytosterols, and N-3 fatty acids improves cardiovascular risk profile in overweight women. Metabolism. 2003;52:771-7.
103. Han J, Hamilton JA, Kirkland JL, Corkey BE, Guo W. Medium-chain oil reduces fat mass and down-regulates expression of adipogenic genes in rats. Obes Res. 2003;11:734-44.
104. St-Oge MP, Ross R, Parsons WD, Jones PJH. Medium-chain triglycerides increase energy expenditure and decrease adiposity in overweight men. Obes Res. 2003;11:395-402.
105. Lei T, Xie W, Han J, Corkey BE, Hamilton JA, Guo W, Medium-chain fatty acids attenuate agonist-stimulated lipolysis, mimicking the effects of starvation. Obes Res. 2004;12:599-611.
106. Habeck M. A succulent cure to end obesity. Drug Discov Today. 2002;7:280-1.
107. Lankisch M, Layer P, Rizza RA, DiMango EP. Acute postprandial gastrointestinal and metabolic effects of wheat amylase inhibit (WAI) in normal, obese, and diabetic humans. Pancreas. 1998;17:176-81.
108. Baek JS, Kim HY, Abbott TP, et al. Acarviosine-simmondsin, a novel compound obtained from acarviosine-glucose and simmondsin by Thermus maltogenic amylase and its in vivo effect on food intake and hyperglycemia. Biosci Biotechnol Biochem. 2003;67:532-9.
109. Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr. 2000;137:43-9.
110. Shadid S, Jensen MD. Effects of growth hormone administration on human obesity. Obes Res. 2003;11:170-5.
111. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;2779:E501-7.
112. Heffernan MA, Thornburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25:1442-9.
113. Berdainier CD, Parente JA Jr, McIntosh MK. Is dehydroepiandrosterone an antiobesity agent? FASEB J. 1993;7:414-9.
114. Wellman M, Shane-McWhorter L, Orlando PL, Jennings P. The role of dehydroepiandrosterone in diabetes mellitus. Pharmacotherapy. 1999;19:582-91.
115. Engeli S, Bohnke J, Feldpausch M, et al. Regulation of 11 beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes. Res. 2004;12:9-17.
116. Walker BR. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity. Obes Res. 2004;12:1-3.
117. Smith SR, Jonge DL, Pellymounter M, et al. Peripheral administration of human corticotropin-releasing hormone: a novel method to increase energy expenditure and fat oxidation in man. J Clin Endocrinol Metab. 2001;86:1991-8.
118. Hirsch J, Leibel RL. The genetics of obesity. Hosp Pract. 1998;33:55-70.
119. Polla MO, Tottie L, Norden C, et al. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa). Bioorg Med Chem. 2004;12:1151-75.
120. Makimura H, Mizuno TM, Yang XJ, Silverstein J, Beasley J, Mobbs CV. Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting. Diabetes. 2001;50:733-9.
121. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP. C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U.S.A. 2002;99:9096-7.
122. Current Patents Gazette. Aventis claims anorexiant indanones and indanols, and their use in controlling obesity: two unidentified candidates with this indication are in clinical trials. http://www.current-patents.com/news/ 2003/0311/11.asp (accessed March 2004).
123. Ganaera. Development - other programs. http://www.genaera.com/ otherprograms.html (accessed March 2004).
124. Phoenix Pharmaceutical Inc. Obesity related peptide list. Available at: http://www.phoenixpeptide.com/allobesity/index.html (accessed July 2004).
125. Thearle M, Aronne LJ. Obesity and pharmacologic therapy. Endocrinol Metab Clin. 2003;32:1005-24.